儿童多发性硬化症:通过高效疗法改善治疗结果
Lama Saleh Aljomah1, E Ann Yeh1
1Department of Pediatrics (Neurology), SickKids Research Institute, Division of Neurosciences and Mental Health, Hospital for Sick Children, University of Toronto, Toronto, Canada.
概括
儿科发病多发性硬化症 (MS) 带来了独特的挑战,包括认知能力下降和侵袭性疾病活动. 早期诊断和治疗对于改变POMS疾病的过程至关重要.
科学领域:
- 神经学 神经学
- 儿科 儿科 儿科
- 免疫学 免疫学 免疫学
背景情况:
- 儿科发病多发性硬化症 (POMS) 影响18岁以下的个体,比成人发病的MS更糟糕的认知功能和更高的疾病活性.
- 及时诊断和早期干预对于修改POMS进展至关重要.
研究的目的:
- 审查儿童多发性硬化症的诊断标准.
- 讨论POMS的差异诊断.
- 检查POMS.目前和新兴的治疗策略.
主要方法:
- 对儿科多发性硬化症的诊断标准的文献综述.
- 分析与POMS相关的差异诊断.
- 评估现有临床试验和现实世界关于POMS疾病修饰疗法 (DMT) 的数据.
- 简要介绍正在进行的临床试验和POMS的新疗法.
主要成果:
- 很少有DMT被FDA批准用于儿科MS,需要非标签使用,并得到现实世界的证据支持.
- 现有证据支持某些DMT在儿科患者群体中的有效性和安全性.
- 目前正在进行的研究和新兴疗法显示POMS治疗的前景.
结论:
- 早期识别和干预POMS对于改善长期结果至关重要.
- 以现实数据为指导的非标签使用DMT目前对于管理POMS至关重要.
- 对儿科专用疗法的持续研究是必要的,以优化POMS护理.
相关概念视频
01:28Drug Therapy
107
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
107
01:26Modeling in Therapy
153
Modeling, a key technique in therapy, uses observational learning to help clients acquire and practice new skills by watching therapists demonstrate desired behaviors. This approach, rooted in Albert Bandura's concept of vicarious learning, plays a significant role in therapeutic interventions for various psychological conditions, including social anxiety, ADHD, and depression.
Participant Modeling
Participant modeling involves therapists demonstrating calm and effective behaviors in...
Participant Modeling
Participant modeling involves therapists demonstrating calm and effective behaviors in...
153
01:20Myasthenia Gravis: Overview and Treatment
2.0K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
2.0K